Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study

By sjmartinez • April 14, 2024

Buch MH, Bhatt DL, Charles-Schoeman C, Giles JT, Mikuls T, Koch GG, Ytterberg S, Nagy E, Jo H, Kwok K, Connell CA, Masri KR, Yndestad A. Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study. RMD Open. 2024 Apr 12;10(2):e003912. doi: 10.1136/rmdopen-2023-003912. PMID: 38609322.

Tags: Antirheumatic Agents, Arthritis, cardiovascular diseases, Publications, Rheumatoid, Rheumatology, Therapeutics, tumor necrosis factor inhibitors

Neighborhood-level characteristics as effect modifiers on the efficacy of the MyPEEPS mobile intervention in same-sex attracted adolescent men

Cordoba E, Garofalo R, Kuhns LM, Pearson C, Scott Batey D, Janulis P, Jia H, Bruce J, Hidalgo MA, Hirshfield S, Radix A, Belkind U,[...]

Editorial: Improving the delivery of pre-exposure prophylaxis (PrEP) to eliminate vertical HIV transmission

Njuguna I, Saidi F, Joseph Davey D, Chi BH, Pintye J. Editorial: Improving the delivery of pre-exposure prophylaxis (PrEP) to eliminate vertical HIV transmission. Front[...]

COVID-19 pandemic and trends in clinical outcomes and medication use for patients with established atrial fibrillation: A nationwide analysis of claims data

Hernandez I, Yang L, Tang S, Cameron T, Guo J, Gabriel N, Essien UR, Magnani JW, Gellad WF. COVID-19 pandemic and trends in clinical outcomes[...]